Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TBPH message board posts where the ticker symbol TBPH has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TBPH SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.02
Acc-no: 0001104659-18-060457 (34 Act)  Size: 19 KB
2018-10-04 001-36033
181106945
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-011431 Size: 4 KB
2018-09-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-011003 Size: 4 KB
2018-08-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010824 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010823 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010822 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010821 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010820 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010819 Size: 4 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-010818 Size: 4 KB
2018-08-22
More TBPH SEC Filings


Related news from
Mon, 15 Oct 2018
21:06:55 +0000
Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
Thu, 11 Oct 2018
12:30:00 +0000
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from multiple studies of YUPELRI™ (revefenacin) inhalation solution were presented at the 2018 CHEST annual meeting, which was held in San Antonio, Texas on October 6-10, 2018. The Prescription Drug User Fee Act (PDUFA) date for YUPELRI is November 13, 2018. If approved, YUPELRI would be the first and only once-daily, long-acting nebulized bronchodilator for the treatment of COPD. YUPELRI is designed to be compatible with any standard jet nebulizer.
Wed, 10 Oct 2018
12:30:00 +0000
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
DUBLIN, Oct. 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that the results from the Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis have been selected for oral presentation as part of the late-breaker session at United European Gastroenterology (UEG) Week 2018.  The presentation will highlight data from the Phase 1b clinical trial of TD-1473 in patients with moderately-to-severely active ulcerative colitis. UEG Week 2018 is being held October 20-24, 2018, in Vienna, Austria.
Tue, 09 Oct 2018
16:01:11 +0000
Can Theravance Biopharma Inc (NASDAQ:TBPH) Improve Your Portfolio Returns?
If you’re interested in Theravance Biopharma Inc (NASDAQ:TBPH), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/can-theravance-biopharma-inc-nasdaqtbph-improve-your-portfolio-returns/">Read More...</a></div>
Mon, 08 Oct 2018
14:29:03 +0000
Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more
Our weekly Health Care Digest gets your week off to a newsy start with Allogene's upsized IPO, a fresh round of capital for an East Bay ag-bio, a new CEO at an inhaled insulin developer and marketing questions for a San Francisco e-cigarette maker.
Mon, 08 Oct 2018
12:30:00 +0000
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that data from studies of YUPELRI™ (revefenacin) will be presented at the 2018 CHEST annual meeting, being held in San Antonio, Texas on October 6-10, 2018. Researchers will also report data from a new study comparing outcomes for YUPELRI and tiotropium (Spiriva® HandiHaler®) in COPD patients with suboptimal peak inspiratory flow rates (PIFR). YUPELRI is an investigational long-acting muscarinic antagonist (LAMA) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.
Mon, 08 Oct 2018
12:03:35 +0000
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Short interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Mon, 08 Oct 2018
11:30:00 +0000
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV® (telavancin) were presented at IDWeek™ 2018, which was held in San Francisco, CA, on October 3 – 7, 2018. Two presentations were made reporting new data from the ongoing Telavancin Observational Use Registry (TOUR™) study, which is designed to report how VIBATIV® (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings.
Sun, 07 Oct 2018
17:00:00 +0000
3 Small Biotech Stocks to Watch in the Fourth Quarter
The S&P 500 had a good summer. The widely followed index rose more than 7% in the third quarter. It was the best quarterly performance for the S&P 500 since 2013. Profits among S&P 500 companies grew some 25% year over year in the first half of 2018 bolstered by robust domestic economic activity and a big drop in the corporate income tax rate.
Mon, 01 Oct 2018
12:05:00 +0000
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018
Data from TOUR™ Patient Registry Highlight Positive Clinical Response Rates in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Focus on Renal ...
Wed, 26 Sep 2018
15:10:03 +0000
Theravance Up as CHMP Backs Trelegy Elipta Line Extension
Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.
Tue, 25 Sep 2018
12:30:00 +0000
Theravance Biopharma to Present at the 2018 Cantor Global Healthcare Conference
DUBLIN, Sept. 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 1:40 p.m. ET.  The conference will be held from October 1 - 3 at the Intercontinental Barclay Hotel in New York. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
Mon, 24 Sep 2018
12:30:00 +0000
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
DUBLIN, Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. Trelegy Ellipta is the triple combination therapy of FF/UMEC/VI in a single ELLIPTA® inhaler.
Tue, 18 Sep 2018
22:36:10 +0000
Theravance, Mylan Report Positive Data on COPD Drug Yupelri
Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.
Mon, 17 Sep 2018
12:30:00 +0000
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.
Tue, 11 Sep 2018
20:22:00 +0000
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, being held in Paris, France on September 15-19, 2018. The presented data will highlight chronic obstructive pulmonary disease (COPD) exacerbation rates observed in the Phase 3 clinical program of YUPELRI in patients with moderate to very severe COPD.
Fri, 31 Aug 2018
16:15:04 +0000
Theravance Bio (TBPH) Up 2.6% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 02 Aug 2018
16:35:04 +0000
Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "No friend, no book, no broker, no advisor, no expert has ever provided a tenth what I am able to find here. The best money I have EVER spent, is for membership." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards